ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ProQR Therapeutics N.V.NASDAQ: PRQR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of €3.21M fell 0.7% year over year, behind the +6.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.

Context

  • Selling, general & admin amounted to 92.4% of revenue in FY2025, up 20.2 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of €79.38M (+462.2%) for the fiscal year ending Dec 2026, a step up from the +3.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€3.21M+0.9% QoQ
Last fiscal yearDec 2025
€14.12M+3.4% YoY
LTMMar 2026
€14.33M+6.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.7%+270.9%+271.7 pp
1 year+3.4%+462.2%+458.9 pp
3-year CAGR-8.9%+152.0%+160.9 pp
5-year CAGR+103.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
14.12M EUR
Year-over-year change
+3.4%
4-year CAGR
-5.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.6% is the 4th highest of 11, against a peer median of -0.7%.
  • Selling, general & admin amounts to 106.6% of revenue for PRQR, versus a peer median of 146.1%.
PRQR Competitors
Selling, General & Admin for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M USD+54.0%+20.4%117.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M USD-29.2%-11.0%120.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M USD+4.0%+10.2%712.8%
ZURAZura Bio LimitedLTM Mar 2026$35.14M USD+1.0%+112.2%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M USD+76.0%+43.8%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M USD+58.7%+29.7%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M USD-28.1%-0.2%3951.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding PRQR) —-0.7%+8.2%146.1%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.